[{"address1": "Jerusalem BioPark", "address2": "2nd floor Hadassah Ein Kerem Campus", "city": "Jerusalem", "country": "Israel", "phone": "972 8 930 2529", "fax": "972 8 930 2531", "website": "https://www.scinai.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center G\u00f6ttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.", "fullTimeEmployees": 31, "maxAge": 86400, "priceHint": 4, "previousClose": 3.92, "open": 3.75, "dayLow": 3.5201, "dayHigh": 3.9999, "regularMarketPreviousClose": 3.92, "regularMarketOpen": 3.75, "regularMarketDayLow": 3.5201, "regularMarketDayHigh": 3.9999, "beta": 2.452, "volume": 48527, "regularMarketVolume": 48527, "averageVolume": 544885, "averageVolume10days": 3347350, "averageDailyVolume10Day": 3347350, "bid": 3.6, "ask": 3.68, "bidSize": 100, "askSize": 100, "marketCap": 2092111, "fiftyTwoWeekLow": 2.23, "fiftyTwoWeekHigh": 18.7, "fiftyDayAverage": 4.14188, "twoHundredDayAverage": 5.93547, "currency": "USD", "enterpriseValue": 6701495808, "floatShares": 1425747874, "sharesOutstanding": 581142, "sharesShort": 603, "sharesShortPriorMonth": 2253, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.001, "heldPercentInsiders": 0.18537001, "heldPercentInstitutions": 0.070539996, "shortRatio": 0.43, "shortPercentOfFloat": 0.004, "impliedSharesOutstanding": 5811420, "bookValue": -9.841, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -6500000, "trailingEps": -16.0, "lastSplitFactor": "1:10", "lastSplitDate": 1716249600, "enterpriseToEbitda": -729.057, "52WeekChange": -0.7446809, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SCNI", "underlyingSymbol": "SCNI", "shortName": "Scinai Immunotherapeutics Ltd.", "longName": "Scinai Immunotherapeutics Ltd.", "firstTradeDateEpochUtc": 1431351000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3111570f-b99f-34c6-94ec-6afda707f452", "messageBoardId": "finmb_9300995", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.6, "targetHighPrice": 700.0, "targetLowPrice": 700.0, "targetMeanPrice": 700.0, "targetMedianPrice": 700.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 4870000, "totalCashPerShare": 0.003, "ebitda": -9192000, "totalDebt": 20561000, "quickRatio": 2.942, "currentRatio": 3.06, "returnOnAssets": -0.2724, "freeCashflow": -5904250, "operatingCashflow": -9382000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]